Vectors for the treatment of autoimmune disease

Gene Therapy

Volumn 10, Issue 10, 2003, Pages 912-927

  Gould, D J ^a   Favorov, P ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Autoimmunity; Regulated gene expression; Targeting; Vectors

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN E; BETA GALACTOSIDASE; BETA INTERFERON; CYTOKINE RECEPTOR; DNA; ECDYSONE; FIBROBLAST GROWTH FACTOR 2; INSULIN DERIVATIVE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 4; LENTIVIRUS VECTOR; MIFEPRISTONE; NAKED DNA; NERVE GROWTH FACTOR; PLASMID DNA; PREPROENKEPHALIN; PREPROINSULIN; RAPAMYCIN; RETROVIRUS VECTOR; STREPTOGRAMIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DNA VECTOR; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

AUTOIMMUNE DISEASES; CLINICAL PROTOCOLS; DEPENDOVIRUS; DNA; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; RETROVIRIDAE; SAFETY; SIMPLEXVIRUS;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; HERPES; LENTIVIRUS; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0038485615     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302018     Document Type: Review

References (197)

1. Yovandich J, O'Malley Jr B, Sikes M, Ledley FD. Gene transfer to synovial cells by intra-articular administration of plasmid DNA. Hum Gene Ther 1995; 6: 603-610.
2. Wolff JA et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
3. Mir LM et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96: 4262-4267.
4. Ohashi S et al. Successful genetic transduction in vivo into synovium by means of electroporation. Biochem Biophys Res Conmmun 2002; 293: 1530-1535.
5. Lin CR et al. Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Therapy 2002; 9: 1247-1253.
6. Zhang L, Nolan E, Kreitschitz S, Rabussay DP. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim Biophys Acta 2002; 1572: 1-9.
7. Budker V et al. The efficient expression of intravascularly delivered DNA in rat muscle. Gene Therapy 1998; 5: 272-276.
8. Prud'homme GJ, Lawson BR, Chang Y, Theofilopoulos AN. Immunotherapeutic gene transfer into muscle. Trends Immunol 2001; 22: 149-155.
9. Watanabe K et al. Protection against autoimmune myocarditis by gene transfer of interleukin-10 by electroporation. Circulation 2001; 104: 1098-1100.
10. Martinenghi S et al. Human insulin production and amelioration of diabetes in mice by electrotransfer-enhanced plasmid DNA gene transfer to the skeletal muscle. Gene Therapy 2002; 9: 1429-1437.
11. Youssef S et al. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest 2000; 106: 361-371.
12. Wildbaum G, Netzer N, Karin N. Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 5885-5892.
13. Fan GC, Singh RR. Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J Exp Med 2002; 196: 731-741.
14. Krieg AM et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
15. MacColl G et al. Intramuscular plasmid DNA injection can accelerate autoimmune responses. Gene Therapy 2001; 8: 1354-1356.
16. Madry H, Trippel SB. Efficient lipid-mediated gene transfer to articular chondrocytes. Gene Therapy 2000; 7: 286-291.
17. Fellowes R et al. Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery. Gene Therapy 2000; 7: 967-977.
18. Croxford JL et al. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1998; 160: 5181-5187.
19. Koh JJ et al. Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD mice. Gene Therapy 2000; 7: 2099-2104.
20. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta 2002; 1575: 1-14.
21. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921.
22. Auricchio A et al. Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. Gene Therapy 2002; 9: 963-971.
23. Ghivizzani SC et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA 1998; 95: 4613-4618.
24. Croxford JL et al. Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. Eur J Immunol 1998; 28: 3904-3916.
25. Takiguchi M et al. CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice. Life Sci 2000; 66: 991-1001.
26. Fleck M et al. Treatment of chronic sialadenitis in a murine model of Sjogren's syndrome by local fasL gene transfer. Arthritis Rheum 2001; 44: 964-973.
27. Matsui Y et al. Blockade of T cell costimulatory signals using adenovirus vectors prevents both the induction and the progression of experimental autoimmune myocarditis. J Mol Cell Cardiol 2002; 34: 279-295.
28. De Kozak Y et al. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin Exp Immunol 2002; 130: 212-223.
29. Whalen JD et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999; 162: 3625-3632.
30. Song K et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000; 191: 1095-1104.
31. Miagkov AV et al. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998; 95: 13859-13864.
32. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-2245.
33. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 2002; 13: 3-13.
34. Parks RJ et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570.
35. Hardy S et al. Construction of adenovirus vectors through Crelox recombination. J Viral 1997; 71: 1842-1849.
36. Chen L, Anton M, Graham FL. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat Cell Mol Genet 1996; 22: 477-488.
37. Schiedner G et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-183.
38. Morral N et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816-12821.
39. Kim IH et al. Lifetime correction of genetic deficiency in mice with a single injection of helper-deperident adenoviral vector. Proc Natl Acad Sci USA 2001; 98: 13282-13287.
40. Zou L, Zhou H, Pastore L, Yang K. Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol Ther 2000; 2: 105-103.
41. Kotin RM et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87: 2211-2215.
42. Urcelay E et al. Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein. J Viral 1995; 69: 2038-2046.
43. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
44. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63: 3822-3828.
45. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000; 6: 433-440.
46. Zolotukhin S et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.
47. Rinaudo D et al. Conditional site-specific integration into human chromosome 19 by using a ligand-dependent chimeric adenoassociated virus/Rep protein. J Virol 2000; 74: 281-294.
48. Kaplitt MG et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
49. Xiao X, Li J, Samulski RJ. Efficient long-term gene transter into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108.
50. Snyder RO et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
51. Flotte TR et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993; 90: 10613-10617.
52. Brockstedt DG et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 1999; 92: 67-75.
53. Moskalenko, M et al. Epitope mapping of human anti-adenoassociated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000; 74: 1761-1766.
54. Chirmule N et al. Immune responses to adenovirus and adenoassociated virus in humans. Gene Therapy 1999; 6: 1574-1583.
55. Jindal RM, Karanam M, Shah R. Prevention of diabetes in the NOD mouse by intra-muscular injection of recombinant adenoassociated virus containing the preproinsulin II gene. Int J Exp Diabetes Res 2001; 2: 129-138.
56. Goody K et al. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci USA 2001; 98: 13913-13918.
57. Yang Z et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer, J Immunol 2002; 168: 6479-6485.
58. Lee HC et al. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature 2000; 408: 483-488.
59. Goater J et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol 2000; 27: 983-989.
60. Zhang HG et al. Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Hum Gene Ther 2000; 11: 2431-2442.
61. Cottard V et al. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Therapy 2000; 7: 1930-1939.
62. Apparailly F et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther 2002; 13: 1179-1188.
63. Burton EA et al. Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells 2001; 19: 358-377.
64. Palmer JA et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J Virol 2000; 74: 5604-5618.
65. Oligino T et al. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Therapy 1999; 6: 1713-1720.
66. Wilson SP et al. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA 1999; 96: 3211-3216.
67. Braz J et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 2001; 21: 7881-7888.
68. Broberg E et al. Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Therapy 2001; 8: 769-777.
69. Furlan R et al. Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Therapy 2001; 8: 13-19.
70. Poliani PL et al. Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Therapy 2001; 12: 905-920.
71. Ruffini F et al. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Therapy 2001; 8: 1207-1213.
72. Goss JR et al. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes 2002; 51: 2227-2232.
73. Kurian KM, Watson CJ, Wyllie AH. Retroviral vectors. Mol Pathol 2000; 53: 173-176.
74. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
75. Tarner I, Fathman C. The potential for gene therapy in the treatment of autoimmune disease. Clin Immunol 2002; 104: 204.
76. Boyle DL et al. Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2 activity. Gene Therapy 1999; 6: 1911-1918.
77. Morita Y et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107: 1275-1284.
78. Zipris D, Karnieli E. A single treatment with IL-4 via retrovirally transduced lymphocytes partially protects against diabetes in BioBreeding (BB) rats. JOP 2002; 3: 76-82.
79. Nakajima A et al. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin Invest 2001; 107: 1293-1301.
80. Melo ME et al. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 2002; 168: 4788-4795.
81. Chen C et al. A gene therapy approach for treating T-cell-mediated autoimmune diseases. Blood 2001, 97: 886-894.
82. Dreja H, Annenkov A, Chernajovsky Y. Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis. Arthritis Rheum 2000; 43: 1698-1709.
83. Evans CH et al. Clinical trials in the gene therapy of arthritis. Clin Orthop 2000; S300-S307.
84. Cavazzana-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
85. Buckley R. Gene therapy for SCID - a complication after remarkable progress. Lancet 2002; 360: 1185-1186.
86. Ketteler R et al. Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors. Gene Therapy 2002; 9: 477-487.
87. Daly G, Chernajovsky Y. Recent developments in retroviral-mediated gene transduction. Mol Ther 2000; 2: 423-434.
88. Naldini L et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
89. Yee JK, Friedmann T, Burns JC. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 1994; 43: 99-112.
90. Dull T et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
91. Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 1997; 94: 10319-10323.
92. Kafri T et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17: 314-317.
93. Miyoshi H et al. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999; 283: 682-686.
94. Korin YD, Zack JA. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 1998; 72: 3161-3168.
95. Srinivasakumar N, Schuening FG. A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery. J Virol 1999; 73: 9589-9598.
96. Zufferey R et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
97. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72: 811-816.
98. Follenzi A et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-222.
99. Sirven A et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 2000; 96: 4103-4110.
100. Scherr M et al. Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/ SCID-repopulating cells. Blood 2002; 99: 709-712.
101. Dardalhon V et al. Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Therapy 2001; 8: 190-198.
102. Woods NB et al. Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. Blood 2000; 96: 3725-3733.
103. Douglas J, Kelly F, Evans JT, Garcia JV. Efficient transduction of human lymphocytes and CD34+ cells via human immunodeficiency virus-based gene transfer vectors. Hum Gene Ther 1999; 10: 935-945.
104. Ramezani A, Hawley TS, Hawley RG. Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther 2000; 2: 458-469.
105. Mikkola H et al. Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells. J Viral 2000; 74: 11911-11918.
106. Demaison C et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813.
107. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892.
108. Salmon P et al. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 2000; 96: 3392-3398.
109. Zufferey R et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
110. Graphodatsky AS et al. Comparative cytogenetics of hamsters of the genus Calomyscus. Cytogenet Cell Genet 2000; 88: 296-304.
111. Pfeifer A et al. Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc Natl Acad Sci USA 2001; 98: 11450-11455.
112. Cui Y et al. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 2002; 99: 399-408.
113. Lotti F et al. Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement. J Virol 2002; 76: 3996-4007.
114. Gao Z et al. High levels of transgene expression following transduction of long-term NOD/ SCID-repopulating human cells with a modified lentiviral vector. Stem Cells 2001; 19: 247-259.
115. Hanawa H et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 2002; 5: 242-251.
116. Maurice M et al. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 2002; 99: 2342-2350.
117. Klages N, Zufferey R, Trono D. A stable system for the hightiter production of multiply attenuated lentiviral vectors. Mol Ther 2000; 2: 170-176.
118. Farson D et al. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 2001; 12: 981-997.
119. D'Costa J et al. Human immunodeficiency virus type 2 lentiviral vectors: packaging signal and splice donor in expression and encapsidation. J Gen Virol 2001; 82: 425-434.
120. Matukonis M et al. Development of second- and third-generation bovine immunodeficiency virus-based gene transfer systems. Hum Gene Ther 2002; 13: 1293-1303.
121. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4: 354-357.
122. Schnell T et al. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 2000; 11: 439-447.
123. Duisit G et al. Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol Ther 2002; 6: 446.
124. Mangeot PE et al. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J Virol 2000; 74: 8307-8315.
125. Gouze E et al. In vivo gene delivery to synovium by lentiviral vectors. Mol Ther 2002; 5: 397-404.
126. Pan D et al. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther 2002; 6: 19-29.
127. Follenzi A et al. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002; 13: 243-260.
128. VandenDriessche T et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002; 100: 813-822.
129. Gallichan WS et al. Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum Gene Ther 1998; 9: 2717-2726.
130. Woods NB et al. Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood 2002; 17: 17.
131. Bukovsky AA, Song JP, Naldini L. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 1999; 73: 7087-7092.
132. Costa GL et al. Targeting rare populations of murine antigenspecific T lymphocytes by retroviral transduction for potential application in gene therapy for autoimmune disease. J Immunol 2000; 164: 3581-3590.
133. Lavillette D, Russell SJ, Cosset FL. Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol 2001; 12: 461-466.
134. Valsesia-Wittmann S et al. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol 1996; 70: 2059-2064.
135. Peng KW et al. A gene delivery system activatable by disease-associated matrix metalloprotenases. Hum Gene Ther 1997; 8: 729-738.
136. Engelstadter M et al. Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library. Hum Gene Ther 2000; 11: 293-303.
137. Russell SJ, Cosset FL. Modifying the host range properties of retroviral vectors. J Gene Med 1999; 1: 300-311.
138. Peng KW et al. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Therapy 2001; 8: 1456-1463.
139. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567-2583.
140. Rea D et al. Highly efficient transduction of human monocyte-derived dendrific cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001; 166: 5236-5244.
141. Stecher H, Shayakhmetov DM, Stamatoyannopoulos G, Lieber A. A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. Mol Ther 2001; 4: 36-44.
142. Asada-Mikami R et al. Efficient gene transduction by RGD-fiber modified recombinant adenovirus into dendritic cells. Jpn J Cancer Res 2001; 92: 321-327.
143. Krasnykh V et al. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001; 75: 4176-4183.
144. Lee LL et al. Identification of synovium-specific homing peptides by in vivo phage display selection. Arthritis Rheum 2002; 46: 2109-2120.
145. Clackson T Regulated gene expression systems. Gene Therapy 2000; 7: 120-125.
146. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
147. Gossen M et al. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
148. Yao F et al. Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther 1998; 9: 1939-1950.
149. Rivera VM et al. A humanized system for pharmacologic control of gene expression. Nat Med 1996; 2: 1028-1032.
150. No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 1996; 93: 3346-3351.
151. Wang Y, O'Malley Jr BW, Tsai SY, O'Malley BW. A regulatory system for use in gene transfer. Proc Natl Acad Sci USA 1994; 91: 8180-8184.
152. Fussenegger M et al. Streptogramin-based gene regulation systems for mammalian cells. Nat Biotechnol 2000; 18: 1203-1208.
153. Hofmann A, Nolan GP, Blau HM. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sci USA 1996; 93: 5185-5190.
154. Iida A, Chen ST, Friedmann T, Yee JK. Inducible gene expression by retrovirus-mediated transfer of a modified tetracycline-regulated system. J Virol 1996; 70: 6054-6059.
155. Lindemann D, Patriquin E, Feng S, Mulligan RC. Versatile retrovirus vector systems for regulated gene expression in vitro and in vivo. Mol Med 1997; 3: 466-476.
156. S AM, Hawkins RE. Efficient transgene regulation from a single tetracycline-controlled positive feedback regulatory system. Gene Therapy 1998; 5: 76-84.
157. Strathdee CA, McLeod MR, Hall JR. Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector. Gene 1999; 229: 21-29.
158. Reiser J, Lai Z, Zhang XY, Brady RO. Development of multigene and regulated lentivirus vectors. J Virol 2000; 74: 10589-10599.
159. Gould DJ et al. A novel doxycycline inducible autoregulatory plasmid which displays "on"/"off" regulation suited to gene therapy applications. Gene Therapy 2000; 7: 2061-2070.
160. Pollock R et al. Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc Natl Acad Sci USA 2000; 97: 13221-13226.
161. Ogueta SB, Yao F, Marasco WA. Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector. Mol Med 2001; 7: 569-579.
162. Bohl D, Heard JM. Modulation of erythropoietin delivery from engineered muscles in mice. Hum Gene Ther 1997; 8: 195-204.
163. Bohl D, Naffakh N, Heard JM. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat Med 1997; 3: 299-305.
164. Favre D et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adenoassociated virus. J Virol 2002; 76: 11605-11611.
165. Urlinger S et al. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000; 97: 7963-7968.
166. Forster K et al. Tetracycline-inducible expression systems with reduced basal activity in mammalian cells. Nucleic Acids Res 1999; 27: 708-710.
167. Freundlieb S, Schirra-Muller C, Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1999; 1: 4-12.
168. Salucci V et al. Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Therapy 2002; 9: 1415-1421.
169. Moser S et al. Dual-regulated expression technology: a new era in the adjustment of heterologous gene expression in mammalian cells. J Gene Med 2001; 3: 529-549.
170. Feldmann M et al. Is NF-kappaB a useful therapeutic target in rheumatoid arthritis? Ann Rheum Dis 2002; 61(Suppl 2): ii13-ii18.
171. Pan RY et al. Disease-inducible transgene expression from a recombinant adeno- associated virus vector in a rat arthritis model. J Virol 1999; 73: 3410-3417.
172. Pan RY et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000; 43: 289-297.
173. Varley AW, Geiszler SM, Gaynor RB, Munford RS. A two-component expression system that responds to inflammatory stimuli in vivo. Nat Biotechnol 1997; 15: 1002-1006.
174. Bakker AC et al. C3-Tat/HIV-regulated intraarticular human interleukin-1 receptor antagonist gene therapy results in efficient inhibition of collagen-induced arthritis superior to cytomegalovirus-regulated expression of the same transgene. Arthritis Rheum 2002; 46: 1661-1670.
175. Miagkov AV, Varley AW, Munford RS, Makarov SS. Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints. J Clin Invest 2002; 109: 1223-1229.
176. Hollander AP, Corke KP, Freemont AJ, Lewis CE. Expression of hypoxia-inducible factor lalpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001; 44: 1540-1544.
177. Shibata T et al. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys 1998; 42: 913-916.
178. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy Gene Therapy 2000; 7: 493-498.
179. Chen R, Meseck ML, Woo SL. Auto-regulated hepatic insulin gene expression in type 1 diabetic rats. Mol Ther 2001; 3: 584-590.
180. Thule PM, Liu JM. Regulated hepatic insulin gene therapy of STZ-diabetic rats. Gene Therapy 2000; 7: 1744-1752.
181. Halban PA, Kahn SE, Lernmark A, Rhodes CJ. Gene and cell-replacement therapy in the treatment of type 1 diabetes: how high must the standards be set? Diabetes 2001; 50: 2181-2191.
182. Rivera VM et al. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science 2000; 287: 826-830.
183. Bessis N et al. Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA). Clin Exp Immunol 1999; 117: 376-382.
184. Evans CH et al. Results from the first human clinical trial of gene therapy for arthritis. Arthritis Rheum 1999; 42: S170 (Abstract).
185. Losordo DW et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105: 2012-2018.
186. Isner JM et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28: 964-973; discussion 73-75.
187. Baumgartner I et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-1123.
188. Zheng C et al. Evaluation of salivary gland acinar and ductal cell-specific promoters in vivo with recombinant adenoviral vectors. Hum Gene Ther 2001; 12: 2215-2223.
189. Ghazizadeh S, Doumeng C, Taichman LB. Durable and stratum-specific gene expression in epidermis. Gene Therapy 2002; 9: 1278-1285.
190. Lin MT, Wang E, Uitto J, Yoon K. Differential expression of tissue-specific promoters by gene gun. Br J Dermatol 2001; 144: 34-39.
191. Lee M, Han S, Ko KS, Kim SW. Cell type specific and glucose responsive expression of interleukin-4 by using insulin promoter and water soluble lipopolymer. J Control Release 2001; 75: 421-429.
192. Zhou G et al. Three high mobility group-like sequences within a 48-base pair enhancer of the Col2a1 gene are required for cartilage-specific expression in vivo. J Biol Chem 1998; 273: 14989-14997.
193. Shi N et al. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci USA 2001; 98: 12754-12759.
194. Segovia J, Vergara P, Brenner M. Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism. Gene Therapy 1998; 5: 1650-1655.
195. Triantaphyllopoulos K, Croxford J, Baker D, Chernajovsky Y. Cloning and expression of murine IFN beta and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Therapy 1998; 5: 253-263.
196. Mathisen PM et al. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J Exp Med 1997; 186: 159-164.
197. Morita A et al. Development of a Langerhans cell-targeted gene therapy format using a dendritic cell-specific promoter. Gene Therapy 2001; 8: 1729-1737.